Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
INTERFERON BETA-1A
EMD SERONO, A DIVISION OF EMD INC., CANADA
L03AB07
INTERFERON BETA-1A
22MCG
SOLUTION
INTERFERON BETA-1A 22MCG
SUBCUTANEOUS
3X0.5ML
Prescription
Immunomodulatory Agents
Active ingredient group (AIG) number: 0131806001; AHFS:
APPROVED
1998-02-05
REBIF ® Product Monograph Page 1 PRODUCT MONOGRAPH PR REBIF ® (Interferon beta-1a Injection) 22 mcg/0.5 mL and 44 mcg/0.5 mL Solution for Injection in Pre-filled Syringes Multidose 22 mcg × 3 (66 mcg/1.5 mL) Multidose 44 mcg × 3 (132 mcg/1.5 mL) Solution for Injection in Pre-filled Cartridges Immunomodulator EMD SERONO, A DIVISION OF EMD INC., CANADA 2695 North Sheridan Way, Suite 200 Mississauga, Ontario, L5K 2N6 EMD Serono is a business of Merck KGaA, Darmstadt, Germany Date of Approval: February 05, 1998 Date of Revision: February 06, 2020 www.emdserono.ca Submission Control No.: 225158 ® Registered trademark of Merck KGaA, Darmstadt, Germany REBIF ® Product Monograph Page 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 DESCRIPTION................................................................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 47 DOSAGE AND ADMINISTRATION ............................................................................. 47 OVERDOSAGE ............................................................................................................... 48 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 49 STORAGE AND STABILITY ................................................................................ Baca dokumen lengkap